De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Uni-Bio Science Group Beheer

Beheer criteriumcontroles 4/4

De CEO Uni-Bio Science Group's is Frank Zhao, benoemd in Apr2019, heeft een ambtstermijn van 5.5 jaar. De totale jaarlijkse vergoeding van { bedraagt HK$ 900.00K, bestaande uit 67.1% salaris en 32.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.13% van de aandelen van het bedrijf, ter waarde HK$ 620.22K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.2 jaar en 7.8 jaar.

Belangrijke informatie

Frank Zhao

Algemeen directeur

HK$900.0k

Totale compensatie

Percentage CEO-salaris	67.1%
Dienstverband CEO	5.5yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	4.2yrs
Gemiddelde ambtstermijn bestuur	7.8yrs

Recente managementupdates

Recent updates

Uni-Bio Science Group Limited (HKG:690) Surges 35% Yet Its Low P/E Is No Reason For Excitement

Sep 13

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 26% Dive

Jul 29

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 27% Dive

May 27

Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?

Apr 24

Uni-Bio Science Group Limited (HKG:690) Held Back By Insufficient Growth Even After Shares Climb 28%

Jan 22

Uni-Bio Science Group Limited's (HKG:690) Low P/S No Reason For Excitement

Oct 24

Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)

Apr 30

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Nov 22

Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)

Jan 05

Companies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth

Mar 01

Uni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years

Jan 05

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Nov 23

Analyse CEO-vergoeding

Hoe is Frank Zhao's beloning veranderd ten opzichte van Uni-Bio Science Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	HK$99m
Mar 31 2024	n/a	n/a	HK$85m
Dec 31 2023	HK$900k	HK$604k	HK$71m
Sep 30 2023	n/a	n/a	HK$67m
Jun 30 2023	n/a	n/a	HK$63m
Mar 31 2023	n/a	n/a	HK$51m
Dec 31 2022	HK$1m	HK$1m	HK$39m
Sep 30 2022	n/a	n/a	HK$16m
Jun 30 2022	n/a	n/a	-HK$7m
Mar 31 2022	n/a	n/a	-HK$13m
Dec 31 2021	HK$2m	HK$907k	-HK$20m
Sep 30 2021	n/a	n/a	-HK$39m
Jun 30 2021	n/a	n/a	-HK$58m
Mar 31 2021	n/a	n/a	-HK$65m
Dec 31 2020	HK$3m	HK$886k	-HK$71m
Sep 30 2020	n/a	n/a	-HK$63m
Jun 30 2020	n/a	n/a	-HK$54m
Mar 31 2020	n/a	n/a	-HK$26m
Dec 31 2019	HK$3m	HK$600k	HK$2m
Sep 30 2019	n/a	n/a	-HK$14m
Jun 30 2019	n/a	n/a	-HK$30m
Mar 31 2019	n/a	n/a	-HK$85m
Dec 31 2018	HK$227k	n/a	-HK$139m
Sep 30 2018	n/a	n/a	-HK$224m
Jun 30 2018	n/a	n/a	-HK$309m
Mar 31 2018	n/a	n/a	-HK$294m
Dec 31 2017	HK$360k	n/a	-HK$279m

Compensatie versus markt: De totale vergoeding ($USD 115.76K ) Frank } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 233.84K ).

Compensatie versus inkomsten: De vergoeding van Frank is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Frank Zhao (59 yo)

5.5yrs

Tenure

HK$900,000

Compensatie

Mr. Zhi Gang Zhao, also known as Frank, CPA, MSc, has been the Chief Executive Officer and Executive Director of Uni-Bio Science Group Limited since April 8, 2019. He has been the Chief Financial Officer a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kingsley Leung	Executive Chairman of the Board	10.7yrs	HK$1.60m	27.26% HK$ 127.1m
Zhi Gang Zhao	CEO & Executive Director	5.5yrs	HK$900.00k	0.13% HK$ 620.2k
Dawei Chen	Executive Vice Chairman of the Board	7.8yrs	HK$284.00k	2.82% HK$ 13.2m
Kai Du	Financial Controller	2.6yrs	geen gegevens	geen gegevens
Wei Tian	Head of HR & Administration Department	no data	geen gegevens	geen gegevens
Wen Du An	Head of Marketing & Sales	4.2yrs	geen gegevens	geen gegevens
Ya Lei Wen	Head of Manufacture Department	no data	geen gegevens	geen gegevens
HuaNan Zhao	Head of Medicine & Registration Department	no data	geen gegevens	geen gegevens
Jing Li	Head of R&D Department	no data	geen gegevens	geen gegevens
Wing Yan Ho	Company Secretary	2.6yrs	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

43.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 690 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kingsley Leung	Executive Chairman of the Board	10.7yrs	HK$1.60m	27.26% HK$ 127.1m
Zhi Gang Zhao	CEO & Executive Director	10.5yrs	HK$900.00k	0.13% HK$ 620.2k
Dawei Chen	Executive Vice Chairman of the Board	7.8yrs	HK$284.00k	2.82% HK$ 13.2m
Qingshan Ma	Independent Non-Executive Director	5.5yrs	HK$120.00k	geen gegevens
Kai Ming Chow	Independent Non-Executive Director	8.5yrs	HK$120.00k	geen gegevens
Qimin Ren	Independent Non-Executive Director	6.9yrs	HK$120.00k	geen gegevens
Kwok Wing Yau	Non-Executive Director	5.5yrs	HK$120.00k	geen gegevens

7.8yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 690 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).

Uni-Bio Science Group Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2024

Uni-Bio Science Group Limited Appoints Zhang Yanfen as an Executive Director

Less than half of directors are independent

Less than half of directors are independent

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2022

Uni-Bio Science Group Limited Announces Executive Changes

Recent updates

Uni-Bio Science Group Limited (HKG:690) Surges 35% Yet Its Low P/E Is No Reason For Excitement

Uni-Bio Science Group Limited (SEHK:690) commences an Equity Buyback Plan for 616,358,814 shares, representing 10% of its issued share capital, under the authorization approved on May 16, 2024.

Uni-Bio Science Group Limited to Report First Half, 2024 Results on Aug 28, 2024

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 26% Dive

New minor risk - Share price stability

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 27% Dive

Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2024

Full year 2023 earnings released: EPS: HK$0.011 (vs HK$0.006 in FY 2022)

Uni-Bio Science Group Limited to Report Q4, 2023 Results on Mar 27, 2024

Uni-Bio Science Group Limited Announces the Acceptance of its Marketing Application for Diquafosol Sodium Eye Drops by the China National Medical Products Administration

Uni-Bio Science Group Limited (HKG:690) Held Back By Insufficient Growth Even After Shares Climb 28%

Uni-Bio Science Group Limited Announces Approval of Marketing Application of Bogutai (Teriparatide Injection) by the China National Medical Products Administration

Uni-Bio Science Group Limited's (HKG:690) Low P/S No Reason For Excitement

First half 2023 earnings released: EPS: HK$0.006 (vs HK$0.002 in 1H 2022)

Uni-Bio Science Group Limited to Report First Half, 2023 Results on Aug 28, 2023

Uni-Bio Science Group Limited Appoints Zhang Yanfen as an Executive Director

Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)

Full year 2022 earnings released: EPS: HK$0.006 (vs HK$0.003 loss in FY 2021)

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Less than half of directors are independent

First half 2022 earnings released: EPS: HK$0.002 (vs HK$0 in 1H 2021)

Uni-Bio Science Group Limited to Report First Half, 2022 Results on Aug 29, 2022

Uni-Bio Science Group Limited Announces Marketing Application of Bogutai (Teriparatide Injection) Officially Accepted by the China National Medical Products Administration

Less than half of directors are independent

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2022

Uni-Bio Science Group Limited Announces Executive Changes

Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)

Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2021

Uni-Bio Science Group Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Companies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth

Uni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years

Uni-Bio Science Group Limited Announces BOSHUTAI (Acarbose Tablets) Has Been Granted Approval for Marketing in China by the National Medical Products Administration

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Uni-Bio Science Group Limited Updates on the Developmental Potential of the Group's Innovative Biologic Self-Developed Drug Recombinant Exendin-4 Injection

First half earnings released

Uni-Bio Science Group Limited to Report Q1, 2021 Results on Aug 28, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd